IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy.
作者信息
Mammen Andrew L, Sartorelli Vittorio
机构信息
Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States.
出版信息
EBioMedicine. 2015 Mar 28;2(4):274-5. doi: 10.1016/j.ebiom.2015.03.018. eCollection 2015 Apr.
Abstract
摘要
相似文献
1
IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy.
EBioMedicine. 2015 Mar 28;2(4):274-5. doi: 10.1016/j.ebiom.2015.03.018. eCollection 2015 Apr.
2
Drug Discovery of Therapies for Duchenne Muscular Dystrophy.
J Biomol Screen. 2015 Dec;20(10):1189-203. doi: 10.1177/1087057115586535. Epub 2015 May 14.
3
Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2867-76. doi: 10.1161/ATVBAHA.112.301172. Epub 2013 Sep 26.
4
Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
Growth Horm IGF Res. 2012 Apr;22(2):69-75. doi: 10.1016/j.ghir.2012.02.004. Epub 2012 Mar 15.
5
Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
Ann Neurol. 2001 Jun;49(6):706-11.
6
On the path to a Duchenne muscular dystrophy therapy.
R I Med J (2013). 2013 Feb 1;96(2):22-5.
7
Exon-skipping therapy for Duchenne muscular dystrophy.
Lancet. 2011 Aug 13;378(9791):546-7. doi: 10.1016/S0140-6736(11)61028-3. Epub 2011 Jul 23.
8
Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
Pediatr Clin North Am. 2015 Jun;62(3):723-42. doi: 10.1016/j.pcl.2015.03.008. Epub 2015 Apr 20.
9
Porcine models of muscular dystrophy.
ILAR J. 2015;56(1):116-26. doi: 10.1093/ilar/ilv015.
10
Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
J Neurochem. 2016 Jan;136(2):351-62. doi: 10.1111/jnc.13269. Epub 2015 Aug 28.
引用本文的文献
1
Exploring lncRNA-Mediated Mechanisms in Muscle Regulation and Their Implications for Duchenne Muscular Dystrophy.
Int J Mol Sci. 2025 Jun 24;26(13):6032. doi: 10.3390/ijms26136032.
2
Muscle-Derived Bioactive Factors: MyoEVs and Myokines.
Cell Prolif. 2025 Mar;58(3):e13801. doi: 10.1111/cpr.13801. Epub 2024 Dec 30.
3
Beneficial immune-modulatory effects of the N-163 strain of -produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study.
IBRO Neurosci Rep. 2023 Jul 4;15:90-99. doi: 10.1016/j.ibneur.2023.06.007. eCollection 2023 Dec.
4
Regenerative inflammation: When immune cells help to re-build tissues.
FEBS J. 2024 Apr;291(8):1597-1614. doi: 10.1111/febs.16693. Epub 2022 Dec 15.
5
Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations.
Mol Ther Nucleic Acids. 2022 Mar 16;28:231-248. doi: 10.1016/j.omtn.2022.03.009. eCollection 2022 Jun 14.
6
Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin.
Cell Mol Life Sci. 2017 Jul;74(13):2487-2501. doi: 10.1007/s00018-017-2465-5. Epub 2017 Feb 10.
7
Neo-epitope Peptides as Biomarkers of Disease Progression for Muscular Dystrophies and Other Myopathies.
J Neuromuscul Dis. 2016 Aug 30;3(3):333-346. doi: 10.3233/JND-160150.
本文引用的文献
1
Duchenne and Becker muscular dystrophies.
Neurol Clin. 2014 Aug;32(3):671-88, viii. doi: 10.1016/j.ncl.2014.05.002.
2
The mdx mouse model as a surrogate for Duchenne muscular dystrophy.
FEBS J. 2013 Sep;280(17):4177-86. doi: 10.1111/febs.12267. Epub 2013 Apr 22.
3
IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse.
BMC Musculoskelet Disord. 2012 Jun 20;13:106. doi: 10.1186/1471-2474-13-106.
4
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003725. doi: 10.1002/14651858.CD003725.pub3.
5
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy.
Cell Metab. 2008 Jan;7(1):33-44. doi: 10.1016/j.cmet.2007.11.011.
6
Do immune cells promote the pathology of dystrophin-deficient myopathies?
Neuromuscul Disord. 2001 Sep;11(6-7):556-64. doi: 10.1016/s0960-8966(01)00198-5.
7
Prednisone in Duchenne muscular dystrophy.
Lancet. 1974 Dec 14;2(7894):1409-12. doi: 10.1016/s0140-6736(74)90071-3.
Zotero 插件